References
- Rees J. K. H., Gray R. G. Remission induction and postremission therapy in acute myelogenous leukaemia: British MRC study. Haematology and Blood transfusion 1990; 33: 243–248
- Preisler H. D., Davis R. B., Kirschner J. Comparison of three remission induction regimes and two post-induction strategies for the treatment of ANLL. A CALGB study. Blood 1987; 69: 1441–1449
- Gale R. P., Foon K. A. Therapy of acute myelogenous leukaemia. Seminars in Haematology 1987; 24: 40–54
- Champlin R. E., Gajewski J. L., Golde D. W. Treatment of acute myelogenous leukaemia in the elderly. Seminars in Oncology 1989; 16: 51–56
- Appelbaum F. R., Fisher L. D., Thomas E. D., et al. Chemotherapy vs marrow transplantation for adults with acute nonlymphoblastic leukaemia: a five year follow-up. Blood 1988; 72: 179–184
- International Bone Marrow Transplant Registry. Transplant or chemotherapy in acute myelogenous leukaemia. Lancet 1989; i: 1119–1122
- Goldstone A. H., Anderson C. C., Linch D. C., Franklin I. M., et al. Autologous bone marrow transplantation following high-dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia. British J. of Haem. 1986; 64: 529–537
- Rees J. K. H., Gray R. G., Swinsky D., et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; ii: 1236–1241
- Bloomfield C. D., et al. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukaemia. Fourth International Workshop on Chromosomes in Leukaemia. Cancer Genetics and Cytogenetics 1984; 11: 332–360
- Hoyle C. F., De Bastos M., Wheatley K., et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results of MRC's 9th AML trial. Brit. J. Haem. 1989; 72: 45–53
- Preisler H. D., Raza A., Barcos M., et al. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukaemia. J. of Clin. Oncology 1987; 5: 75–82
- Campana D., Coustan-Smith Janossy G. Immunophenotyping in Haematological diagnosis. Bailliere's Clinical Haematology 1990; 3: 889–919
- Benedetto P., Mertelsmann R., Szatrowski T. H., et al. Prognostic significance of terminal deoxynucleotidyl transferase (TdT) activity in acute nonlymphocytic leukaemia. J. of Clin. Oncology 1986; 4: 489–495
- Zutter M. M., et al. CD7+ Acute non-lymphocytic leukaemia: Evidence for an early multipotential progenitor. Leukaemia Research 1990; 14: 23–26
- Cross A. H., et al. Acute myeloid leukaemia with T-lymphocytic features: A distinct biologic and clinical entity. Blood 1988; 72: 579–587
- Bell E. D., et al. Prognostic value of lymphocyte surface markers in acute myeloid leukaemia. Blood 1991; 77: 2242–2250
- Vaughan W. P., et al. Acute leukaemia expressing the normal human haemopoietic stem cell membrane glycoprotein CD34 (My10). Leukaemia 1988; 2: 661–666
- Borowitz M. J., et al. Clinicopathologic and cytogenetic features of CD34 (My10)-positive acute nonlymphoblastic leukaemia. American Journal of Clinical Pathology 1988; 91: 265–270
- Geller R. B., et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br. J. of Haematology 1990; 76: 340–347
- Bennett J. M., et al. Proposed revised criteria for the classification of acute myeloid leukaemia: a report of French-British Cooperative Group. Annals of Int. Medicine 1985; 103: 620–625
- Kaplan E. L., Meier P. Nonparametric estimation from incomplete observation. J. of the American Statistical Association 1958; 53: 457–481
- Peto R. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer 1977; 35: 1–39